Fascinating how no one cares about Acerus any moreThere was a time when many on this board would get all worked up over the ever-devolving situation at Acerus. Now the company has announced its final acts born of desperation, and no one can be bothered even to comment. (Tommy must have fallen off his tractor, and the Contrarian is probably just being contrary again.)
It occurs to me that a one-to-200 reverse split is a great way for Ian to pocket some loose change, which is the one core competency he can claim. According to the plan, those grandmothers sitting on odd lots of, say, 197 shares purchased at a couple of bucks per share, will have their shares essentially confiscated and won't receive a farthing. Well, that's how Ian rolls, isn't it?
As for the deal with "Serenity Now" Pharmaceuticals, this strikes me as a marriage of two hideously deformed wallflowers entered into similar to a spinster obsessed with marrying a prisoner on death row. Here's what Serenity's earlier distribution partner, Avendel, had to say three years ago about the experience trying to market Serentiy's Rx Noctiva: “Noctiva’s performance since launch has been highly disappointing despite a substantial investment of resources. It no longer warrants such a level of support, and Avadel will be better positioned for the future by exiting the business entirely.” That's some great due diligence you did on this deal, Ed.
Details here. Anyway, there's no one left here to complain to, except that weird little man or woman who keeps talking about having a crush on Edward. I'll leave you to it, then. Be seeing you.
05:23 PM EDT, 04/19/2022 (MT Newswires) -- Acerus Pharmaceuticals Corporation (ASP.TO) on Tuesday said it intends to undertake a consolidation of its outstanding common shares on the basis of one post-consolidation share for every 200 pre-consolidation shares.
The consolidation was approved by shareholders at the company's annual meeting held in June, and is subject to the approval of the Toronto Stock Exchange (TSX).